Metabonomics in the preclinical and environmental toxicity field

Abstract

Preclinical studies assess both efficacy and safety of new drugs through a series of assays used to identify potential target organs and determine safety thresholds. However, despite these efforts, too many drugs prove toxic to humans during clinical phases or later on the market. This paper reviews how metabonomics, one of the key players in systems biology, should be able to assist toxicologists in better predicting the adverse effects of xenobiotics.